Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869722 | 1.00 | FOLH1 (0.58) | FOLH1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL8928051 | 0.89 | RNPEP (0.54) | FOLH1ALDH1A1LMNARNPEPGAA | |
| SCHEMBL27602423 | 0.86 | FOLH1 (0.58) | FOLH1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15592739 | 0.83 | LMNA (0.51) | FOLH1ALDH1A1LMNARNPEPGAA | |
| SCHEMBL9911535 | 0.83 | LMNA (0.51) | FOLH1ALDH1A1LMNARNPEPGAA | |
| SCHEMBL8023768 | 0.83 | FNTA (0.43) | FOLH1ALDH1A1LMNARNPEPNPSR1 | |
| SCHEMBL8255152 | 0.81 | RNPEP (0.47) | FOLH1ALDH1A1LMNARNPEPGAA | |
| SCHEMBL8255575 | 0.81 | RNPEP (0.47) | FOLH1ALDH1A1LMNARNPEPGAA | |
| SCHEMBL30642009 | 0.81 | RNPEP (0.47) | FOLH1ALDH1A1LMNARNPEPGAA | |
| SCHEMBL29561871 | 0.81 | RNPEP (0.47) | FOLH1ALDH1A1LMNARNPEPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | FOLH1 229/4885ALDH1A1 1305/4885LMNA 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.